Figure 1 | Scientific Reports

Figure 1

From: FAN score comprising fibrosis-4 index, albumin–bilirubin score and neutrophil–lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab

Figure 1

Probability estimates of the prognosis of the study patients with metastatic urothelial carcinoma who were treated with pembrolizumab. Probability estimates of progression-free survival (PFS) (a) and cancer-specific survival (CSS) (b) for the 165 patients in the discovery cohort. Probability estimates of PFS (c) and CSS (d) for the 103 patients in the validation cohort. CI, confidence interval.

Back to article page